INmune Bio Schedules Feb 26 Webinar to Unveil Phase III RDEB CORDStrom Data
INmune Bio will host a webinar on February 26 to present new MissionEB Phase III data for CORDStrom in recessive dystrophic epidermolysis bullosa patients. The presentation will highlight EBDASI skin score improvements versus placebo, pediatric weight gain, reductions in pain and itch, and enhanced daily function data.
1. Webinar Overview
INmune Bio will host a webinar on February 26, 2026 at 1:00 p.m. ET to present MissionEB Phase III trial data for CORDStrom in RDEB patients. The session will focus on systemic disease-modifying effects beyond topical wound care.
2. Key Clinical Data Highlights
Presenters will review changes in EBDASI skin scores versus placebo, pediatric weight gain metrics addressing failure-to-thrive, observed reductions in pain and itch, and investigator feedback on daily functional improvements.
3. Featured Clinical Experts
Dr. Anna Martinez, principal investigator of the MissionEB trial and leading UK pediatric RDEB specialist, and Prof. Mark Lowdell, INmune Bio’s chief scientific officer, will provide firsthand insights into the systemic rationale and trial execution.